Kim Si-Hyun, Park Chulmin, Chun Hye-Sun, Lee Dong-Gun, Choi Jae-Ki, Lee Hyo-Jin, Cho Sung-Yeon, Park Sun Hee, Choi Su-Mi, Choi Jung-Hyun, Yoo Jin-Hong
1 Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea , Seoul, Republic of Korea.
2 Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea , Incheon St. Mary's Hospital, Incheon, Republic of Korea.
Microb Drug Resist. 2016 Jul;22(5):372-8. doi: 10.1089/mdr.2015.0251. Epub 2016 Mar 14.
With the rise in multidrug-resistant (MDR) bacterial infections, there has been increasing interest in combinations of ≥2 antimicrobial agents with synergistic effects. We established an MDR bacterial strain library to screen for in vitro antimicrobial synergy by using a broth microdilution checkerboard method and high-throughput luciferase-based bacterial cell viability assay. In total, 39 MDR bacterial strains, including 23 carbapenem-resistant gram-negative bacteria, 9 vancomycin-intermediate Staphylococcus aureus, and 7 vancomycin-resistant Enterococcus faecalis, were used to screen for potential antimicrobial synergies. Synergies were more frequently identified with combinations of imipenem plus trimethoprim-sulfamethoxazole for carbapenem-resistant Acinetobacter baumannii in the library. To verify this finding, we tested 34 A. baumannii clinical isolates resistant to both imipenem and trimethoprim-sulfamethoxazole by the checkerboard method. The imipenem plus trimethoprim-sulfamethoxazole combination showed synergy in the treatment of 21 (62%) of the clinical isolates. The results indicate that pilot screening for antimicrobial synergy in the MDR bacterial strain library could be valuable in the selection of combination therapeutic regimens to treat MDR bacterial infections. Further studies are warranted to determine whether this screening system can be useful to screen for the combined effects of conventional antimicrobials and new-generation antimicrobials or nonantimicrobials.
随着多重耐药(MDR)细菌感染的增加,人们对具有协同作用的≥2种抗菌药物组合的兴趣日益浓厚。我们建立了一个MDR细菌菌株库,通过肉汤微量稀释棋盘法和基于荧光素酶的高通量细菌细胞活力测定来筛选体外抗菌协同作用。总共使用了39株MDR细菌菌株,包括23株耐碳青霉烯革兰氏阴性菌、9株万古霉素中介金黄色葡萄球菌和7株耐万古霉素粪肠球菌,以筛选潜在的抗菌协同作用。在该菌株库中,亚胺培南与甲氧苄啶-磺胺甲恶唑联合使用时,更频繁地发现对耐碳青霉烯鲍曼不动杆菌具有协同作用。为了验证这一发现,我们通过棋盘法对34株对亚胺培南和甲氧苄啶-磺胺甲恶唑均耐药的鲍曼不动杆菌临床分离株进行了检测。亚胺培南与甲氧苄啶-磺胺甲恶唑联合用药在21株(62%)临床分离株的治疗中显示出协同作用。结果表明,在MDR细菌菌株库中进行抗菌协同作用的初步筛选,对于选择治疗MDR细菌感染的联合治疗方案可能具有重要价值。有必要进一步研究以确定该筛选系统是否可用于筛选传统抗菌药物与新一代抗菌药物或非抗菌药物的联合效果。